Nothing Special   »   [go: up one dir, main page]

UY32167A - Nuevos derivados de 2-amidotiadiazol - Google Patents

Nuevos derivados de 2-amidotiadiazol

Info

Publication number
UY32167A
UY32167A UY0001032167A UY32167A UY32167A UY 32167 A UY32167 A UY 32167A UY 0001032167 A UY0001032167 A UY 0001032167A UY 32167 A UY32167 A UY 32167A UY 32167 A UY32167 A UY 32167A
Authority
UY
Uruguay
Prior art keywords
amidotiadiazol
new derivatives
derivatives
diseases
amidothiadiazole
Prior art date
Application number
UY0001032167A
Other languages
English (en)
Inventor
Pedro Manuel Grima Poveda
Nuria Aguilar Izquierdo
Marta Mir Cepeda
Manuel Lopez Martinez
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of UY32167A publication Critical patent/UY32167A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Derivados de 2-amidotiadiazol, procedimientos para su preparación y composiciones farmacéuticas que los contienen, útiles para el tratamiento, prevención o supresión de enfermedades y trastornos susceptibles de mejoría por agonistas de los receptores de 1-fosfato de esfingosina (S1P1), tales como las enfermedades inmunes, autoinmunes o inflamatorias crónicas.
UY0001032167A 2008-10-14 2009-10-07 Nuevos derivados de 2-amidotiadiazol UY32167A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08382042A EP2177521A1 (en) 2008-10-14 2008-10-14 New 2-Amidothiadiazole Derivatives

Publications (1)

Publication Number Publication Date
UY32167A true UY32167A (es) 2010-01-05

Family

ID=40386238

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032167A UY32167A (es) 2008-10-14 2009-10-07 Nuevos derivados de 2-amidotiadiazol

Country Status (20)

Country Link
US (1) US20110200557A1 (es)
EP (2) EP2177521A1 (es)
JP (1) JP2012505260A (es)
KR (1) KR20110067034A (es)
CN (1) CN102186847A (es)
AR (1) AR073821A1 (es)
AU (1) AU2009304274A1 (es)
BR (1) BRPI0914371A2 (es)
CA (1) CA2740614A1 (es)
CL (1) CL2011000795A1 (es)
CO (1) CO6321168A2 (es)
EA (1) EA201100612A1 (es)
EC (1) ECSP11010842A (es)
IL (1) IL211290A0 (es)
MX (1) MX2011003692A (es)
PE (1) PE20110420A1 (es)
TW (1) TW201018679A (es)
UY (1) UY32167A (es)
WO (1) WO2010043377A1 (es)
ZA (1) ZA201101236B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6100687B2 (ja) * 2010-08-31 2017-03-22 ダウ アグロサイエンシィズ エルエルシー 農薬組成物
RU2448961C1 (ru) * 2011-02-03 2012-04-27 Открытое акционерное общество "Всероссийский научный центр по безопасности биологически активных веществ" (ОАО "ВНЦ БАВ") Фармацевтическая композиция, обладающая противовоспалительной, бронхолитической, противотуберкулезной активностями
JP5951650B2 (ja) 2011-03-18 2016-07-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ｎ−（３−カルバモイルフェニル）−１ｈ−ピラゾール−５−カルボキサミド誘導体及び害虫を防除するためのそれらの使用
CN102276554B (zh) * 2011-06-28 2013-10-30 四川大学 4-（（2-氨基-5-巯基-1,3,4-噻二唑）-甲基）-苯甲酰胺衍生物及其制备方法和用途
FR2988000A1 (fr) * 2012-03-16 2013-09-20 Thomas Wandji Composition pharmaceutique active dans la therapie des affections virales humaines et animales
WO2014070978A1 (en) * 2012-11-03 2014-05-08 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
US9334249B2 (en) 2012-11-03 2016-05-10 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
WO2014111871A1 (en) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
CN106397149B (zh) * 2016-08-26 2019-05-21 大连奇凯医药科技有限公司 五氟苯甲醛的制备方法
SI3619196T1 (sl) 2017-05-04 2022-10-28 Bayer Cropscience Aktiengesellschaft 2-((2-(feniloksimetil)piridin-5-il)oksi)-etanaminski derivati in sorodne spojine kot sredstva za zatiranje škodljivcev, npr. za zaščito rastlin
RU2672887C1 (ru) * 2018-03-13 2018-11-20 Акционерное общество "Всесоюзный научный центр по безопасности биологически активных веществ (АО "ВНЦ БАВ") N-(5-Этил-1,3,4-тиадиазол-2-ил)-2-пропилпентанамид, обладающий противоэпилептической и обезболивающей активностями
CN114149297A (zh) * 2021-12-07 2022-03-08 北京中医药大学 一种微波辅助的选择性芳基甲醛的绿色合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2303792A (en) 1992-06-23 1994-01-24 Motorola, Inc. Multi-modulation scheme compatible radio
AU719449B2 (en) 1995-06-21 2000-05-11 Astrazeneca Ab Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
IL158324A0 (en) * 2001-04-19 2004-05-12 Bayer Ag Arylsulphonamides as anttiviral agents
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
ES2316758T3 (es) 2002-05-16 2009-04-16 Novartis Ag Uso de aglutinantes del receptor edg en el cancer.
GB0217152D0 (en) 2002-07-24 2002-09-04 Novartis Ag Organic compounds
EP1484057A1 (en) 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
WO2005025553A2 (en) 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
EP1670463A2 (en) * 2003-10-01 2006-06-21 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
JP2009528274A (ja) 2006-01-27 2009-08-06 ユニバーシティ オブ バージニア パテント ファンデーション 神経因性疼痛の治療法
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
EP2046315B1 (en) 2006-06-02 2013-04-10 The Ohio State University Research Foundation Therapeutic agents for the treatment of mantle cell lymphoma
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
ES2393631T3 (es) 2006-08-17 2012-12-26 University Of Chicago Tratamiento de enfermedades inflamatorias
MX2009002234A (es) * 2006-09-08 2009-03-16 Actelion Pharmaceuticals Ltd Derivados de piridin-3-il como agentes inmunomoduladores.
WO2008091967A1 (en) * 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
GB0704394D0 (en) * 2007-03-07 2007-04-11 Senexis Ltd Compounds

Also Published As

Publication number Publication date
CN102186847A (zh) 2011-09-14
AU2009304274A1 (en) 2010-04-22
CO6321168A2 (es) 2011-09-20
US20110200557A1 (en) 2011-08-18
TW201018679A (en) 2010-05-16
IL211290A0 (en) 2011-04-28
KR20110067034A (ko) 2011-06-20
AR073821A1 (es) 2010-12-01
ECSP11010842A (es) 2011-03-31
BRPI0914371A2 (pt) 2019-09-24
CL2011000795A1 (es) 2011-08-19
EA201100612A1 (ru) 2011-12-30
WO2010043377A1 (en) 2010-04-22
EP2177521A1 (en) 2010-04-21
MX2011003692A (es) 2011-04-27
CA2740614A1 (en) 2010-04-22
PE20110420A1 (es) 2011-07-01
EP2334670A1 (en) 2011-06-22
ZA201101236B (en) 2011-09-28
JP2012505260A (ja) 2012-03-01

Similar Documents

Publication Publication Date Title
UY32167A (es) Nuevos derivados de 2-amidotiadiazol
UY32880A (es) Nuevos derivados de tiaziazol
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
ECSP11011517A (es) Compuestos antivirales
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
UY32809A (es) Compuestos y composiciones como inhibidores de cinasa s y k
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CL2015000956A1 (es) Compuestos derivados de pirrolotriazinona como inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; uso para tratar enfermedades respiratorias, autoinmunes, trastornos neurologicos, cardiovasculares, metabolicos, entre otros.
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
CL2007001887A1 (es) Compuestos derivados de bifensustuidas por tetrazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades asociadas con los receptores purinergicos de p2x, tales como trastornos gastrointes
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
NI201200029A (es) Compuestos y composiciones como inhibidores de cinasa de proteína
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
CR20140142A (es) Variantes delfactor 21 del crecimiento de fibroblastos
UY35177A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
NI201400070A (es) Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido.
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
BR112012011478A2 (pt) composições fosfolipídicas terapêuticas concentradas.
UY33735A (es) Compuestos antivirales
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
CR10138A (es) 1h indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
CR20130602A (es) Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa